PITTSBURGH - Viatris Inc. (NASDAQ: NASDAQ:VTRS) today detailed the pricing terms of its subsidiary Utah Acquisition Sub Inc.'s cash tender offer for a portion of its outstanding 3.950% Senior Notes due 2026. The offer, targeting up to $575,003,000 of the notes, follows the defined terms in the Offer to Purchase dated September 4, 2024.
By the early tender deadline on Tuesday, offers for $1,449,950,000 in principal amount of the notes had been submitted, exceeding the maximum tender cap. Consequently, not all tendered notes are expected to be purchased, with the accepted notes subject to a pro rata basis as outlined in the offer document.
The tender offer, which will not accept further notes post the early tender date unless the cap is raised or removed, is set to expire on October 2, 2024. The early settlement date is anticipated to be September 20, 2024, when payment for the accepted notes, including accrued interest, will be made.
This tender offer is part of Viatris' broader financial strategy, which also included the satisfaction and discharge of its 1.650% Senior Notes due 2025 on September 16, 2024, and the redemption notice issued by Mylan Inc . for its 2.125% Senior Notes due 2025, with completion expected by October 16, 2024.
Barclays Capital Inc., Citigroup Global Markets Inc., and J.P. Morgan Securities LLC are acting as lead dealer managers for the tender offer, with Global Bondholder Services Corporation serving as the tender and information agent.
The announcement clarifies that this press release is solely for informational purposes and is not an offer to buy or sell securities. The tender offer is made exclusively through the Offer to Purchase and only in jurisdictions where it is legally permissible.
This news article is based on a press release statement from Viatris Inc. and does not constitute any form of financial advice or endorsement.
In other recent news, Viatris Inc. has reported a robust Q2 for 2024, demonstrating operational revenue growth and significant advancements in its product pipeline. The company's total revenues reached $3.8 billion, marking a 2% increase in operational revenue, and adjusted earnings before interest, taxes, depreciation, and amortization (EBITDA) rose to $1.2 billion. Adjusted earnings per share (EPS) were reported at $0.69. In light of these developments, Viatris has boosted its new product revenue forecast for 2024 to between $500 million and $600 million.
The company also highlighted its strong global presence, robust financial position, and leading cash flow generation in the sector. Viatris is anticipating a year-over-year operational revenue growth of 2% for 2024 and projects over $3 billion available for strategic deployment. The company's research and development focus includes a pipeline for the base business and innovative assets in cardiovascular disease, immunology, and eye care.
Viatris's new product portfolio is performing strongly, with expectations of sustained momentum throughout the year. The company has over 250 products in development or under regulatory review, including complex generics and innovative treatments for diseases with limited options. Furthermore, the company's novel S1P antagonist, Cenerimod, is showing promising results in Phase II trials for lupus.
InvestingPro Insights
Amidst Viatris Inc.'s (NASDAQ: VTRS) active financial maneuvering, including the cash tender offer for its 3.950% Senior Notes, the company's broader market position and outlook provide additional context for investors. With a market capitalization of $14.16 billion, Viatris is a significant player in the pharmaceutical industry. The company's commitment to shareholder returns is evident through aggressive share buybacks, contributing to a high shareholder yield, as noted in one of the InvestingPro Tips. Moreover, analysts predict that Viatris will be profitable this year, aligning with expectations of net income growth.
The company's stock has demonstrated resilience, with a strong return over the last three months, marked by an 18.83% price total return. This performance is particularly noteworthy given the stock's low price volatility, which may appeal to investors seeking stability in their portfolios. On the valuation front, Viatris's adjusted P/E ratio for the last twelve months as of Q2 2024 stands at 15.68, suggesting a reasonable valuation given the company's strong free cash flow yield, another highlight from the InvestingPro Tips.
For those interested in further analysis and metrics, InvestingPro offers additional insights such as revenue growth trends, gross profit margins, and return on assets, providing a comprehensive view of Viatris's financial health. The platform currently lists a total of 10 InvestingPro Tips for Viatris, offering a deeper dive into the company's performance and prospects. These tips, alongside real-time metrics, are available at https://www.investing.com/pro/VTRS, offering valuable resources for investors considering Viatris Inc. in their investment strategy.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.